« Back
Home /
Enoticumab Biosimilar（Anti-DLL4 Reference Antibody）

Enoticumab Biosimilar（Anti-DLL4 Reference Antibody）

Item no.	DCC-A883-100mg
Manufacturer	DCChemicals
CASRN	1192578-27-0
Amount	100 mg
Category	In Vivo
Applications	IV
Specific against	other
Available
Manufacturer - Applications	Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 100 mg

available

Delivery expected until 12/11/2025

Compare

Add to wishlist

Get an offer

Request delivery time